MFA
PTCT icon

Mayflower Financial Advisors’s PTC Therapeutics PTCT Stock Holding History

Mayflower Financial Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,113
Closed -$206K – 359
2022
Q3 		$206K Sell
4,113
-2,039
-33% -$99.9K 0.03% 305
2022
Q2 		$246K Sell
6,152
-3
-0% -$105 0.04% 286
2022
Q1 		$230K Buy
+6,155
New +$237K 0.03% 305
2021
Q3 		– Sell
-4,770
Closed -$202K – 348
2021
Q2 		$202K Buy
+4,770
New +$204K 0.03% 303

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Mayflower Financial Advisors's PTCT Position: Q4 2022 in Review

Mayflower Financial Advisors sold out of PTC Therapeutics (PTCT) in Q4 2022, closing a stake of 4,113 shares — an estimated $206K sold.

Mayflower Financial Advisors first reported a position in PTCT in Q2 2021 and held it in 4 quarters. The position peaked at $246K in Q2 2022. 202 funds tracked by Wall St. Rank hold PTCT as of Q4 2022.

  • Mayflower Financial Advisors reported no remaining PTC Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Mayflower Financial Advisors sold 4,113 PTC Therapeutics shares in Q4 2022, an estimated $206K.
  • Mayflower Financial Advisors first reported a position in PTC Therapeutics in Q2 2021 and held it in 4 quarters.
  • Mayflower Financial Advisors's PTC Therapeutics position peaked at $246K in Q2 2022.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2022.

Based on Mayflower Financial Advisors's 13F filing for Q4 2022, filed 19 Jan 2023.